Cognitive Behavioural Therapy (CBT)

CBT's Rising Role in Migraine Management

Migraine remains a major public health challenge in Canada, affecting an estimated 8-10% of the population and ranking as a leading cause of disability among working-age adults. Recent provincial data from Alberta highlight the financial toll: individuals with migraine incur 1.5 times higher annual healthcare costs than matched controls, with an average incremental expense of $2,806 per person in 2022 dollars. Prescription medications account for the largest share of this added burden.

Chronic migraine exacts an even steeper price, with incremental costs exceeding $5,000 annually per patient. Scaled nationally, migraine could contribute over $1 billion in extra direct healthcare spending yearly in a single large province, underscoring the urgency for cost-effective strategies beyond drugs alone.

The Canadian Headache Society's 2025 update to its migraine prevention guidelines marks a pivotal shift. Building on approvals of anti-CGRP monoclonal antibodies and gepants between 2018 and 2024, the guidelines expand recommendations for episodic and chronic migraine prevention. Yet they also maintain support for established non-drug options, including behavioural therapies, amid recognition that pharmacological advances have not fully resolved access issues, high costs, or side-effect concerns for all patients.

Global and North American evidence from 2024-2025 reinforces CBT's value. Meta-analyses show it reduces headache frequency by roughly 1-2 days per month compared with no treatment, with effects comparable to face-to-face or digital delivery formats. Combined behavioural-pharmacological approaches, often delivered via telehealth, promise broader reach and better outcomes, particularly as medication shortages, insurance hurdles, and expense limit reliance on newer agents.

Tensions persist between rapid pharmaceutical innovation and practical realities. While CGRP-targeted therapies offer targeted relief with fewer systemic side effects than older preventives, their cost and coverage variability leave many patients underserved. Behavioural interventions like CBT address psychological factors—stress, anxiety, hypervigilance—that amplify migraine cycles, offering a low-risk complement or alternative without exacerbating medication-overuse risks. This layered approach reflects growing consensus that optimal management requires integrating mind and body strategies in a resource-constrained system.